
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are rallying higher Thursday after the company announced the FDA has granted Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi syndrome.
The co-exclusive license allows Tonix to expand its intranasal potentiated oxytocin development program to a new indication.